Pharmacists Warned: Diverted HIV Medicines Sold on Online P2P Platforms Pose Serious Patient Risk
Key Insights
ADAP Advocacy (search) and the Partnership for Safe Medicines (search) issued a joint warning that all discounted HIV medicines on pharmacy-to-pharmacy (P2P) online marketplaces should be considered suspect products under FDA guidelines and the Drug Supply Chain Security Act.
Gilead Sciences filed a Lanham Act suit in April 2026 against ten pharmacies and 15 individuals for allegedly selling diverted, misbranded, and counterfeit Gilead-branded HIV medicines through P2P platforms.
Deeply discounted listings—such as Biktarvy at $1,999 (53% off WAC)—meet multiple FDA risk criteria for illegitimacy, including unknown sellers, incomplete transaction histories, and an established pattern of fraud in the HIV drug supply chain.
The Partnership for Safe Medicines (search) (PSM) and ADAP Advocacy (search) issued an urgent joint warning on June 30, 2026, alerting pharmacists across the United States that discounted HIV medicines purchased from online pharmacy-to-pharmacy (P2P) marketplaces qualify as suspect products under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act (DSCSA). The organizations are calling on pharmacies to immediately cease buying HIV medicines from these platforms and to quarantine and verify all existing inventory obtained through such channels.
The warning follows a Lanham Act suit filed by Gilead Sciences in April 2026 against ten pharmacies and 15 individuals for allegedly selling diverted, misbranded, infringing, and counterfeit Gilead-branded HIV medicines to pharmacies nationwide via online P2P marketplaces. The defendants are presumed innocent until the claims are adjudicated.
A Pattern of Fraud in the HIV Drug Supply Chain
This latest litigation echoes previous civil cases brought by Gilead Sciences in the name of patient protection. Gilead Sciences v. Safe Chain Solutions et al (2021) and Gilead Sciences v. Peter Khaim et al (2024) similarly involved the sale of unsafe medicine through P2P sales, and both led to criminal prosecutions of major participants. In those earlier cases, defendants collected bottles of medicine from patients, removed identifying information, refilled and resealed them, forged pedigrees, and slipped them back into the legitimate drug supply via distributors.
In the current case against Pain Relief Rx et al, Gilead asserts that the defendants obtained medication that had previously been dispensed to patients and resold it as new through P2P platforms to pharmacies around the country.
PSM's Executive Director, Shabbir Imber Safdar, stated: "A deeply discounted HIV product bought off the internet from an unknown seller who won't provide a pedigree qualifies as suspect even before the purchasing pharmacy receives it because the listing alone meets many of the U.S. Food and Drug Administration's risk criteria for illegitimacy: deep discounts, an established pattern of fraud in the HIV drug supply chain over the last six years, unknown sellers, and incomplete transaction histories. Once received, the often-observed damage to the packaging confirms that this product will need to be quarantined and investigated."
How Suspect Products Are Identified
The warning provides a detailed case example. In December 2025, a pharmacist searching the P2P marketplace RxPost for Gilead's Biktarvy and Descovy found listings at $1,999 and $1,099 respectively—discounts of roughly 53% and 50% off the Wholesale Acquisition Price (WAC). Upon receiving the product, the pharmacist observed that the medical outsert was missing and the label was damaged, with sticky residue and smearing consistent with the use of a solvent to remove a prescribing label.
Even before purchase, the listing met multiple FDA risk criteria for suspicious products: purchasing from an unknown source on the internet, a price "too good to be true," a trading partner reluctant to provide transaction history, and a product class with an established history of counterfeiting and diversion. While the FDA does not specify a threshold number of criteria, the organizations note that five criteria should be sufficient for any reasonable person to determine a product is suspect.
Quarantine and Verification Obligations
Once a pharmacy has custody of suspect product, FDA guidance requires trading partners to have systems in place to quarantine suspect product and promptly conduct an investigation. Quarantine involves physically separating suspect products from verified sources, updating database records to prevent further distribution, and assigning a responsible person to terminate quarantine once verification is complete.
Verification, however, is substantially more burdensome. It requires validating transaction history and transaction information, actively communicating with the manufacturer and trading partners, and tracing the product's provenance through the supply chain. The guidance emphasizes: "There is no suspect product that is cheap enough that it is worth it for a community pharmacy to conduct a full investigation."
Vulnerable Platforms and Informal Trading
The current suit alleges that defendants sold diverted products on InStockRx, Rxeed, Rx-Post, and RxWorld. Other P2P platforms identified as potentially vulnerable include CityRx, EzriRx, MatchRX, RedSail RxMarket, StockMeds, and TradeNetRx.
Brandon M. Macsata, CEO of ADAP Advocacy (search), added: "Independent pharmacies have also been known to trade stock in less formal settings such as WhatsApp or Telegram. Those transactions are, if anything, more vulnerable and never advisable. We're strongly urging pharmacists to heed our warning and avoid exposing patients to unnecessary risks."
Recommendations and Patient Resources
PSM and ADAP Advocacy (search) recommend that Boards of Pharmacy study the alert and consider warning licensees about the dangers of purchasing HIV medicines from P2P platforms. The organizations further urge P2P platforms to disallow sales of HIV medicines entirely.
For patients living with HIV who need assistance with medication costs, the organizations highlighted several resources, including the AIDS Drug Assistance Program (ADAP), the TotalAssist Program (formed through the merger of Patient Advocate Foundation and PAN Foundation), HarborPath, the HealthWell Foundation, and RxAssist.
All P2P transactions are conducted under a DSCSA exemption, which the organizations state makes platform claims of "DSCSA compliance" both misleading and meaningless to patient safety. However, there is no exception in the law for product verification investigations: if a seller's product is determined to be suspect, they must provide information about where they purchased it.